BioInvent International AB: Interim report January–September 2024 is out. Read the report: bioinvent.com/en/press/bioin…

Busy days #ESMO2024 - European Society for Medical Oncology 2024 - in Barcelona. Today, the BioInvent team presents a Trial in Progress poster for the company’s second anti-TNFR2 antibody, BI-1910. Read the full poster: bioinvent.com/en/our-science…

BioInvent International Interim Report January-June 2024 released today: bioinvent.com/en/node/1266

BioInvent to Present Pipeline Progress at ESMO in September 2024. Two posters to be presented on early clinical projects from BioInvent’s robust pipeline totaling six clinical programs. - Progress Phase 1 update for BI-1910 - Initial Phase 1 clinical data for BT-001

BioInvent Presents Poster Highlighting Model-Informed Early Clinical Development of anti-TNFR2 agent BI-1808 at PAGE 2024 bioinvent.com/en/press/bioin…

BioInvent Presents Promising Clinical Efficacy and Safety for anti-TNFR2 agent BI-1808 and Promising Phase 1 Data for BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Solid Tumors at ASCO 2024. bioinvent.com/en

BioInvent presents additional promising Phase 1/2a data at EHA 2024 for BI-1206 with rituximab in NHL. Read the press release: bioinvent.com/en/press/bioin…

BioInvent International AB Interim report January-March 2024 just released: bioinvent.com/en/investors/f…

BioInvent International AB Annual report 2023 is now published. Read the full report: bioinvent.com/en/press/bioin…

BioInvent announces a new clinical trial collaboration and supply agreement with MSD to evaluate BI-1910, the company’s second anti-TNFR2 antibody in combination with KEYTRUDA® (pembrolizumab) bioinvent.com/en/press/bioin…

CEO Martin Welschof on stage at the BIO & CEO conference in New York getting ready for a corporate presentation at 1 pm local time. bcic.bio.org BioInvent.com #immunooncology #Immunotherapy

BioInvent International AB Year-end report January 1 – December 31, 2023 bioinvent.com/en/press/bioin…

Invitation to presentation of Year-end report 2023 When: Thursday February 22, 2024, at 2:00 pm CET. Listen to the presentation webcast: financialhearings.com/event/… To participate via teleconference, please register via the following link: conference.financialhearings….